Oral oncology · 2025
Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Deng Jie, Murphy Barbara A, Andersen Lucy P, McMenamin Erin, Lukens John N, Cohn Joy C, Rajasekaran Karthik, Quinn Ryan J, Spinelli Bryan A, Lin Alexander
Аннотация
OBJECTIVES: Survivors of head and neck cancer (HNC) are at high risk for developing lymphedema and fibrosis (LEF). Once diagnosed with LEF, survivors must engage in a lifelong program of self-care to minimize long-term adverse effects. However, evidence-based LEF self-management (SM) programs are lacking. To fill this void, we developed and pilot-tested a LEF-SM program for HNC survivors.
MATERIALS AND METHODS: The LEF-SM Program was developed using the Information-Motivation-Behavioral Skills model of health behavior change as a framework. The program was pilot tested in a three-group randomized controlled trial evaluating feasibility and preliminary efficacy. Fifty-nine participants were randomized to: Usual care (n = 20), usual care plus LEF-SM Program (n = 20), and usual care plus LEF-SM Program plus lymphedema therapist follow-up (n = 19). Assessments were conducted at baseline, 3-, 6-, 9-, and 12-month. Outcomes included feasibility and preliminary efficacy (LEF progression, symptom burden, and jaw range of motion). Multivariate covariance pattern model analysis was used to test differences between groups.
RESULTS: 1) Feasibility: 97.4% of the participants completed three of three planned LEF self-management skill training sessions, 92.1% completed at least two of three planned motivational interviewing sessions, and 82.3% completed at least two of three planned lymphedema therapist follow-up sessions. Participant satisfaction with the LEF-SM Program was high. No adverse events were reported. 2) Preliminary Efficacy: Compared to usual care, LEF-SM Program (± follow-up) showed a decrease in LEF severity and symptom burden (p < 0.05).
CONCLUSION: The LEF-SM Program is feasible and potentially efficacious. Further testing is warranted for this novel program addressing an unmet need for HNC survivors.
TRIAL REGISTRATION: This study was registered on January 22, 2017, at ClinicalTrials.gov, a service of the US National Institute of Health (NCT03030859). The URL of the trial registry record:https://www.
CLINICALTRIALS: gov/study/NCT03030859.
MATERIALS AND METHODS: The LEF-SM Program was developed using the Information-Motivation-Behavioral Skills model of health behavior change as a framework. The program was pilot tested in a three-group randomized controlled trial evaluating feasibility and preliminary efficacy. Fifty-nine participants were randomized to: Usual care (n = 20), usual care plus LEF-SM Program (n = 20), and usual care plus LEF-SM Program plus lymphedema therapist follow-up (n = 19). Assessments were conducted at baseline, 3-, 6-, 9-, and 12-month. Outcomes included feasibility and preliminary efficacy (LEF progression, symptom burden, and jaw range of motion). Multivariate covariance pattern model analysis was used to test differences between groups.
RESULTS: 1) Feasibility: 97.4% of the participants completed three of three planned LEF self-management skill training sessions, 92.1% completed at least two of three planned motivational interviewing sessions, and 82.3% completed at least two of three planned lymphedema therapist follow-up sessions. Participant satisfaction with the LEF-SM Program was high. No adverse events were reported. 2) Preliminary Efficacy: Compared to usual care, LEF-SM Program (± follow-up) showed a decrease in LEF severity and symptom burden (p < 0.05).
CONCLUSION: The LEF-SM Program is feasible and potentially efficacious. Further testing is warranted for this novel program addressing an unmet need for HNC survivors.
TRIAL REGISTRATION: This study was registered on January 22, 2017, at ClinicalTrials.gov, a service of the US National Institute of Health (NCT03030859). The URL of the trial registry record:https://www.
CLINICALTRIALS: gov/study/NCT03030859.